Company: CDT
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001246
Chunk: 44

Company: CDT Equity Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 1A
Chunk 44
---
 had no reasonable cause to believe such person’s conduct was unlawful;

    ●
    We
    may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law;

    ●
    We
    will be required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except
    that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled
    to indemnification;

54

    ●
    We
    will not be obligated pursuant to our Bylaws to indemnify a person with respect to proceedings initiated by that person against us
    or our other indemnitees, except with respect to proceedings authorized by our board of directors;

    ●
    the
    rights conferred in our Bylaws are not exclusive, and we are authorized to enter into indemnification agreements with our directors,
    officers, employees and agents and to obtain insurance to indemnify such persons; and

    ●
    we
    may not retroactively amend our Bylaw provisions to reduce our indemnification obligations to directors, officers, employees and
    agents.

Risks
Related to Finances and Capital Requirements

We
will require substantial additional funding in the future, which may not be available to us on acceptable terms, or at all, and, if not
so available, may require us to delay, limit, reduce, or cease our operations.

Our
operations have consumed substantial amounts of cash since our inception. As of December 31, 2024, we had an accumulated deficit of $29.1
million and our net loss was $17.8 million for the fiscal year ended December 31, 2024. We expect to continue to incur significant expenses
and increasing operating losses for the foreseeable future. Our business will require substantial additional capital for implementation
of our long-term business plan and development of clinical assets. Our ability to raise additional funds may be adversely impacted by
potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in
the U.S. As we require additional funds, we may seek to fund our operations through the sale of additional equity securities, debt financing,
and/or strategic collaboration agreements. We cannot be sure that additional financing from any of these sources will be available when
needed or that, if available, the additional financing will be obtained on favorable terms.

Our
future funding requirements will depend on many factors, including,